Media.Player

Water-soluble Polymer-based Cantharimides as Potentially Selective Anti-tumor Agents

Summary

A cantharimide compound may include the backbone of formula (1). R1, R2, R3, and R4 may be independently selected from the group consisting of H, C(O)OR5, C(O)R6, C(O)NR7R8, NR9C(O)R10, N—R11R12, O—R13, S—R14, P(O)(OR15)(OR16), As(O)(OR17)(OR18), SO2R19, SO3R20, and B(OR21). X1to X4 may be independently selected from the group consisting of nitrogen and carbon, such that X1 to X4 are not all hydrogen. Y1, Y2 and R5 to R21 may be independently selected from the group consisting of hydrogen, C1-12-alkyl, -aryl, heteroaryl, and a bioactive polymer.

Supplementary Information

Patent Number: US8344007B2
Application Number: US2009428488A
Inventor: Tang, Johnny Cheuk-on | Chan, Albert Sun-chi | Lam, Kim-hung | Chui, Chung-hin | Kok, Stanton Hon Lung | Yuen, Marcus Chun Wah | Chan, Sau Hing | Cheng, Chor Hing | Cheung, Filly
Priority Date: 23 Apr 2009
Priority Number: US8344007B2
Application Date: 23 Apr 2009
Publication Date: 1 Jan 2013
IPC Current: A01N004378 | A61K003141
US Class: 514367 | 548159
Assignee Applicant: The Hong Kong Polytechnic University
Title: Water-soluble polymer-based cantharimides as potentially selective anti-tumor agents
Usefulness: Water-soluble polymer-based cantharimides as potentially selective anti-tumor agents
Summary: (I) are useful for treating an adverse health condition, which is a proliferative disorder or a cancer, where the cancer is e.g. acute myelogenous leukemia, hepatocellular carcinoma (all claimed), osteosclerotic myeloma, plasma cell leukemia, benign monoclonal gammopathy, fibrosarcoma, carcinosarcoma, colon cancers, rectal cancers, non-small cell lung cancer, squamous cell carcinoma, adenocarcinoma, prostate cancers, rhabdomyosarcoma, and thyroid cancer. (I) are useful for preventing, treating, managing, or ameliorating: one or more symptoms of a disorder associated with cellular hyperproliferation; and a secondary condition (e.g. a viral, bacterial, or fungal infection). (I) are useful as a food additive, a dietary supplement, and a cosmetic composition, and in the preparation of foodstuffs such as baked goods, meat products with fillers (e.g. hamburgers and sausages), cereals, pastas, and soups. The ability of (I) to treat cancer was tested using hepatocellular carcinoma cell lines (Hep3B). The result showed that IC 50 value of 2-((1R,2S,6R,7S)-2,6-dimethyl-3,5-dioxo-10-oxa-4-aza-tricyclo-dec-4-yl)-benzothiazole-6-carboxylic acid was 5 g/ml.
Novelty: New cantharimide compounds useful e.g. for treating an adverse health condition, which is proliferative disorder or cancer e.g. acute myelogenous leukemia, hepatocellular carcinoma, osteosclerotic myeloma, fibrosarcoma and colon cancers

Industry

Biomedical

Sub Category

Medical Composition

Application No.

US2009428488A

Others

CHAN Sun-chi Albert
TANG Cheuk-on Johnny
LAM Kim-hung
CHUI Chung-hin
KOK Hon Lung Stanton
YUEN Chun Wah Marcus
CHAN Sau Hing
CHENG Chor Hing; CHEUNG Filly

Country/Region

USA